A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Regorafenib (Primary)
- Indications Ewing's sarcoma; Liposarcoma; Osteosarcoma
- Focus Therapeutic Use
- 02 Jun 2017 Results of a substudy (n=30) from REGO arm in advanced Ewing sarcoma patients presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 24 Apr 2017 Planned End Date changed from 1 Feb 2017 to 1 Dec 2019.
- 24 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2019.